NYSE:MRK 14 August 2025 - 28 May 2026

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares moved higher on Tuesday. The stock outperformed biotech funds, which took a hit, as investors focused on upcoming management meetings and stayed active trading Ligand’s pending XOMA Royalty deal. The Nasdaq-listed stock was trading at $233.11 as of 12:53 p.m. EDT, up 1.4%. The SPDR S&P Biotech ETF was down 3.8% and the iShares Nasdaq Biotechnology ETF slid 3.0%. The SPY ETF, which tracks the S&P 500, edged up 0.1% and the QQQ, which follows the Nasdaq 100, added 0.4%.
June 2, 2026
BeOne Dips on Wall Street After Cancer Results, Market Looks On
·······

BeOne Dips on Wall Street After Cancer Results, Market Looks On

BeOne Medicines AG shares lost ground Thursday afternoon even as the biotech sector moved higher. Investors took in fresh late-stage cancer data, but enthusiasm around the company’s oncology pipeline already looked priced in. ONC slipped 2.7% to $291.98 at 2:57 p.m. EDT. The Nasdaq Biotechnology Index was up 1.1%. The gap stood out after BeOne shared a new update that came in positive on the science. Still, traders didn’t show much appetite for ONC ahead of more ASCO data due next week.
May 28, 2026
Exelixis Up After Merck Pact Focuses Attention on Cancer Study
·····

Exelixis Up After Merck Pact Focuses Attention on Cancer Study

Exelixis shares climbed Wednesday after the company announced a new Merck partnership, putting its next cancer drug program further into late-stage trials. Shares traded 2.5% higher at $49.89 in the afternoon, putting the Alameda, California-based company’s market cap near $13.3 billion. Biotech stocks were strong, with the iShares Nasdaq Biotechnology ETF up 1.8% and the SPDR S&P Biotech ETF up 3.8%.
May 20, 2026
How Engineering Nature’s Catalysts is Transforming Medicine, Food & the Planet
··········

The Enzyme Revolution: How Engineering Nature’s Catalysts is Transforming Medicine, Food & the Planet

Imagine if we could reprogram nature’s own microscopic machines to solve human problems. Enzyme engineering is the science of redesigning enzymes – the proteins that catalyze life’s chemistry – to have new or improved functions. In simple terms, it means tweaking an enzyme’s genetic code so the enzyme works better or differently. Why bother? Because enzymes are extraordinary catalysts: they speed up chemical reactions under gentle conditions, unlike many industrial processes that require high heat or toxic chemicals newsroom.uw.edu. As biochemist David Baker explains, “Living organisms are remarkable chemists… they use enzymes to break down or build up whatever they need under gentle conditions. New enzymes could put renewable chemicals and biofuels within reach” newsroom.uw.edu. In other words, if we
August 14, 2025